Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregnenolone for Depression in People with HIV
NCT05570812Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pregnenolone in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Started Mar 2023; status: recruiting.
02
Drugs
pregnenolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05570812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05570812.